The first new antimicrobial chemistry in a generation.— The innovation the world has been waiting for.
Patent-protected. Plant-derived. Independently validated. A platform technology engineered to replace the world's most problematic preservatives and antimicrobials — at global scale.
A novel, patent-protected active with a new mechanism of action. Plant-derived. Water-soluble. Clean-manufactured. A natural, green-manufactured alternative to parabens, silver and PHMB across the world's most demanding regulated applications.
- Patent-protected · novel mechanism
- 36-month real-time stability complete
- Engaging founding partners under NDA
Headline figures shown. Full third-party study reports available under NDA.
A foundational shift in how preservatives are made.
Conventional antimicrobials face mounting pressure: rising microbial resistance, tightening global regulation, supply fragility and a consumer shift away from synthetic actives. Our platform addresses all of it from first principles.
Clean by design
Plant-derived from a renewable feedstock via a proprietary, patent-protected activation process. No harsh synthetics.
Broad-spectrum performance
Independent kill-time, antiviral and 3-year stability data — biofilm work described by the University of Glasgow as world-class.
Built for global scale
Water-soluble, plentiful global supply, low-cost manufacture — engineered for premium markets and global hygiene alike.
Biofilms & antibiotic resistance. The world needs better preservation.
Over 80% of chronic infections involve biofilms — structured bacterial communities that are up to 1,000× more resistant to conventional antimicrobials. This is the challenge our platform was built to address.
Rising microbial tolerance and resistance to conventional actives.
Regulatory pressure on parabens, silver and PHMB across major markets.
Limited effectiveness of many incumbents against persistent biofilms.
Cost, supply and sustainability constraints in emerging markets.
Antibiotic resistance is outpacing the pipeline.
The WHO has named antimicrobial resistance one of the top ten global public health threats facing humanity. Decades of over-reliance on a narrow set of actives has driven tolerance, cross-resistance and treatment failure — while the discovery pipeline for genuinely new chemistries has all but stalled.
The world doesn't need another derivative of an existing class. It needs a new mechanism, a new feedstock, and a new manufacturing base — proven against the organisms that matter today.
Annual deaths attributable to bacterial AMR worldwide.
Annual deaths associated with bacterial AMR worldwide.
Projected annual deaths by 2050 if AMR continues unchecked.
Cumulative global economic cost projected by 2050.
Public-domain figures cited for context. AGP does not claim clinical antibiotic indications.
Biofilms are where conventional antimicrobials quietly fail.
Once microorganisms attach to a surface and form a biofilm — whether on a stainless-steel processing line or a chronic wound bed — they can become up to 1,000× more tolerant to antimicrobials than their planktonic counterparts. This single mode of survival underlies two of the most expensive problems in modern industry.
Persistent contamination on the line.
Listeria, Salmonella and E. coli establish resilient biofilms inside drains, conveyors, gaskets and cold-chain equipment. Standard CIP regimes can knock down planktonic cells while leaving the biofilm matrix intact — seeding repeat contamination batch after batch.
- ≈ 600mFoodborne illness cases globally each year (WHO).
- $110bn+Annual cost of unsafe food in low- and middle-income economies (World Bank).
- ≥ 60%Of food-industry contamination events linked to biofilm reservoirs in published surveys.
The reason chronic wounds don't heal.
Biofilms are present in the majority of chronic wounds — diabetic foot ulcers, venous leg ulcers and pressure injuries — where they sustain inflammation and stall re-epithelialisation. Silver, PHMB and chlorhexidine dressings can struggle against mature P. aeruginosa and S. aureus biofilms.
- ≈ 80%Of chronic wounds contain a clinically significant biofilm.
- $25bn+Annual U.S. healthcare spend on chronic wound management.
- 1,000×Tolerance increase of biofilm-embedded organisms vs. planktonic cells.
Independent biofilm work conducted on our active at the University of Glasgow has been described as world-class — outperforming a 0.2% chlorhexidine benchmark against P. aeruginosa biofilms in an alginate-hydrogel wound model.
Industry figures: WHO, World Bank, U.S. CDC, peer-reviewed surveys. Internal study reports available under NDA.
Clear. Viscous. Quietly extraordinary.
A clear, viscous, water-soluble liquid produced from a renewable plant feedstock with abundant global supply — through a clean, single-step activation process. Engineered to integrate seamlessly into formulations across regulated and consumer applications.
- Appearance
- Clear, viscous liquid
- Solubility
- Fully water-soluble
- Origin
- Renewable plant feedstock
- Supply
- Plentiful, globally
- Manufacture
- Clean, single-step activation
- Cost
- Engineered for scale
Composition and process disclosed under NDA.
Why incumbents are failing — and we are not.
The dominant antimicrobial and preservative chemistries in use today carry compounding cost, supply, regulatory and safety burdens. Our active was engineered from first principles to avoid every one of them.
- AGPOur active
- Yes
- ParabensConventional preservatives
- No
- SilverSilver dressings / ions
- No
- PHMBPolyhexamethylene biguanide
- No
- AGPOur active
- Yes
- ParabensConventional preservatives
- No
- SilverSilver dressings / ions
- No
- PHMBPolyhexamethylene biguanide
- No
- AGPOur active
- Yes
- ParabensConventional preservatives
- Limited
- SilverSilver dressings / ions
- No
- PHMBPolyhexamethylene biguanide
- Yes
- AGPOur active
- Yes
- ParabensConventional preservatives
- No
- SilverSilver dressings / ions
- Variable
- PHMBPolyhexamethylene biguanide
- Variable
- AGPOur active
- Yes
- ParabensConventional preservatives
- No
- SilverSilver dressings / ions
- Limited
- PHMBPolyhexamethylene biguanide
- Limited
- AGPOur active
- Yes
- ParabensConventional preservatives
- Yes
- SilverSilver dressings / ions
- No
- PHMBPolyhexamethylene biguanide
- Constrained
- AGPOur active
- Yes
- ParabensConventional preservatives
- Yes
- SilverSilver dressings / ions
- No
- PHMBPolyhexamethylene biguanide
- No
- AGPOur active
- Yes
- ParabensConventional preservatives
- Under pressure
- SilverSilver dressings / ions
- Under review
- PHMBPolyhexamethylene biguanide
- Restricted
- AGPOur active
- Under evaluation
- ParabensConventional preservatives
- No
- SilverSilver dressings / ions
- Cytotoxicity concerns
- PHMBPolyhexamethylene biguanide
- Skin sensitisation concerns
Comparative claims based on publicly available regulatory positions and published efficacy literature. Independent test reports for our active available under NDA.
From regulated medical care to global hygiene at scale.
01Wound Care
02Cosmetics & Personal Care
03Oral Care
04Hygiene
05Food Preservation
06Public HealthWe work with the people the rest of the industry trusts.
Our platform has been developed with — and validated by — a deliberate network of UK and international universities, independent test laboratories, patent attorneys, formulation specialists and regulatory advisers. Every claim we make is built on work performed at arm's length by recognised experts.
Specific institutions are named to qualified partners under NDA.
Independent biofilm, microbiology and stability work — including a programme described by the University of Glasgow as world-class.
ISO/ASTM/EN method testing across bactericidal, antiviral, preservative-efficacy and toxicology endpoints.
Specialist UK and international patent attorneys protecting composition, process and application claims.
Cosmetic, wound-care and food-contact experts advising on integration, dossiers and route-to-market.
- UK Russell Group universities
- Accredited microbiology labs
- Specialist IP counsel
- Cosmetic safety assessors
- Wound-care formulators
- Regulatory advisers
Independently validated. Across years, not weeks.
Long-duration stability, kill-time efficacy and validated antiviral performance — all conducted by independent third parties.
Real-time stability
Thirty-six months of real-time shelf-life data across ambient, chilled, frozen and accelerated conditions — not modelled approximations.
Bactericidal kill-time
Greater than 5-log reduction within 60 minutes against S. aureus, E. coli and P. aeruginosa in independent third-party testing.
Antiviral activity
Greater than 4-log virucidal reduction within 5 minutes against enveloped viral targets in validated third-party assays.
Preservative efficacy
Criteria A passed across multiple inclusion levels — supporting use as a standalone or booster preservation system.
MIC / MBC profile
Low minimum inhibitory concentrations against key Gram-positive, Gram-negative and fungal organisms.
Biofilm-model performance
Outperformed 0.2% chlorhexidine benchmark against P. aeruginosa biofilms in an independent alginate-hydrogel model. Further validation required.
Headline figures shown. Full third-party study reports, methods and raw data available to qualified partners under NDA.
The active ingredient remains, for now, a closely held secret.
We are not yet ready to disclose the composition publicly. Qualified partners — formulators, manufacturers, clinicians, regulators and investors — are invited to get in touch. Under a mutual non-disclosure agreement we are able to share the full technical dossier, third-party study reports and a working sample.
Request an NDAA national security issue. A global responsibility.
Antimicrobial resistance is recognised by the WHO, the UN and allied defence reviews as one of the defining security threats of the century — projected to claim ten million lives a year by 2050 and to destabilise health systems, food supply and military readiness in every nation on earth.
Hospital-acquired infection, foodborne disease, biofilm-driven wound failure and the contamination of water and supply chains are not local problems. They cross borders, and so must the response. We invite ministries of health, defence, biosecurity, food security and public-health agencies — in any nation — to open a confidential conversation. We are ready to work with governments prepared to move at the pace the threat demands.
Government & defence enquiriesWe work with a select group of partners.
For partnership, licensing or co-development enquiries, our team will respond personally and in confidence.
Request a conversation- Partnerships
- partnerships@agp-innovation.co.uk
- Investors
- investors@agp-innovation.co.uk
- Registered office
- North Lodge, Armitage Lane, Hawkesyard, Rugeley WS15 1PS, United Kingdom
- Company number
- 13213466 · England & Wales